Buffalo, NY — November 17, 2025 — Leads & Copy —
Positron Corporation (OTC: POSC) has announced it is now an SEC reporting company, marking a significant milestone for the molecular imaging technology and services provider. The company’s transition enhances financial transparency, strengthens corporate governance, and positions Positron for broader institutional visibility as it advances plans to uplist to a senior exchange.
Positron filed a Form 10 registration statement with the SEC, including all required financial statements and disclosures. As a result, the company is now subject to the reporting requirements of the Securities Exchange Act of 1934 and will file quarterly and annual reports with the SEC, along with current reports to provide updates on material events.
Adel Abdullah, CEO of Positron Corporation, stated that becoming an SEC reporting company reflects Positron’s commitment to transparency and to building a world-class company in molecular imaging. He added that the SEC reporting status provides investors, customers, and partners with confidence that Positron operates with the highest standards of accountability.
Positron’s enhanced reporting status comes amid accelerating demand for PET-CT imaging in cardiology and oncology. With its expanding product portfolio, exclusive North American partnership with Neusoft Medical Systems, and a fast-growing pipeline of system sales and service contracts, Positron believes it is strategically positioned to capture significant market share in the years ahead.
Abdullah added that the company expects the milestone to broaden its access to capital markets and support Positron’s long-term growth objectives as it brings high-performance, cost-effective molecular imaging solutions to practices and hospitals across the U.S. and internationally.
Positron Corporation co-develops, manufactures, and sells PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in cardiac PET imaging, offering technologies, clinical services, and practice solutions to diagnose coronary artery disease and improve patient outcomes while practicing cost-effective medicine.
Positron’s PET and PET-CT imaging systems and distinct market position are advantages that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron’s PET-CT systems will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine and to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
The company also has a co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co., a subsidiary of Neusoft Medical Systems, and is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists.
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
info@skylineccg.com
Contact:
investor@positron.com
Source: Positron Corporation
